The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: Azelnidipine and amlodipine

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 1, 2013, Pages 63-69

  Fujisawa, Michio ^a,b   Yorikane, Ryosuke ^b   Matsuoka, Yuko ^b   Koike, Hiroyuki ^b   Ueno, Koichi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

amlodipine; antianginal effect; azelnidipine; rate pressure product; vascular affinity

Indexed keywords

AMLODIPINE; AZELNIDIPINE; CALCIUM; OXYGEN;

ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGINAL EFFECT; ARTICLE; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HEART CONTRACTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ST SEGMENT DEPRESSION;

ADMINISTRATION, ORAL; AMLODIPINE; ANGINA PECTORIS; ANIMALS; ARGININE VASOPRESSIN; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM; CALCIUM CHANNEL BLOCKERS; CORONARY VESSELS; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEART RATE; MALE; MYOCARDIUM; OXYGEN CONSUMPTION; RATS; SWINE; TIME FACTORS; VASOCONSTRICTION;

EID: 84872344430     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182776c28.     Document Type: Article

References (31)

1. Sueda S, Ochi N, Kawada H, et al. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol. 1999;83:1186-1190.
2. Bertrand ME, LaBlanche JM, Tilmant PY, et al. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation. 1982;65:1299-1306.
3. Pristipino C, Beltrame JF, Finocchiaro ML, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation. 2000;101:1102-1108.
4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50:652-726.
5. Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation. 1981;63:844-848.
6. Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med. 1980;302:1269-1273.
7. Yamagishi M, Miyatake K, Tamai J, et al. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. J Am Coll Cardiol. 1994;23:352-357.
8. Tanabe Y, Itoh E, Suzuki K, et al. Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. J Am Coll Cardiol. 2002;39:1120-1126.
9. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46:231-236.
10. Fuke S, Maekawa K, Kawamoto K, et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J. 2007;71:220-235.
11. Ogawa T, Yasui K, Tomizawa T, et al. Safety and efficacy of amlodipine. A new once-daily calcium antagonist in non-hypertensive patients with coronary artery disease. Jpn Heart J. 1993;34:557-565.
12. Navarro Estrada JL, Oliveri R. Long-term efficacy of amlodipine in patients with severe coronary artery disease. J Cardiovasc Pharmacol. 1993;22:S24-S28.
13. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003;26:201-208.
14. Yamagishi T. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. Hypertens Res. 2006;29:767-773.
15. Nada T, Nomura M, Koshiba K, et al. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung. 2007;57:698-704.
16. van Zwieten PA, Pfaffendorf M. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J Hypertens Suppl. 1993;11:S3-S8.
17. Mancia G, Omboni S, Zanchetti A. Clinical advantages of lipophilic dihydropyridines. Blood Press Suppl. 1998;2:23-26.
18. Gaviraghi G, Micheli D, Trist DG. Recent developments in the use of calcium antagonists in myocardial protection. Pharmacol Res. 1995;31: 251-254.
19. Kano S, Ichihara K, Komatsu K, et al. Comparative effects of azelnidipine and amlodipine on myocardial function and mortality after ischemia/reperfusion in dogs. J Pharmacol Sci. 2011;116:181-187.
20. Maturi MF, Martin SE, Markle D, et al. Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of nondiseased small vessels. Circulation. 1991;83:2111-2121.
21. Koike H, Kimura T, Kawasaki T, et al. Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity. Annu Rep Sankyo Res Lab. 2002;54:1-64.
22. Nunoya T, Shibuya K, Saitoh T, et al. Use of miniature pig for biomedical research, with reference to toxicologic studies. J Toxicol Pathol. 2007;20:125-132.
23. Yao K, Shirakura S. Combined effects of benidipine and diltiazem in a rat model of experimental angina. J Pharmacol Sci. 2004;95:394-397.
24. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43:1029-1039.
25. Rhodes DG, Sarmiento JG, Herbette LG. Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site. Mol Pharmacol. 1985;27:612-623.
26. Yamada S, Sugimoto N, Uchida S, et al. Pharmacokinetics of amlodipine and its occupancy of calcium antagonist receptors. J Cardiovasc Pharmacol. 1994;23:466-472.
27. Shokoji T, Fujisawa Y, Kiyomoto H, et al. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res. 2005;28:1017-1023.
28. Oizumi K, Nishino H, Miyake S, et al. Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR. Jpn J Pharmacol. 1990;54:1-6.
29. Fujisawa M, Yorikane R, Chiba S, et al. Chronotropic effects of azelnidipine, a slow-and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine. J Cardiovasc Pharmacol. 2009;53:325-332.
30. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens. 2011; 13:687-689.
31. Rosendorff C. Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease. Expert Opin Pharmacother. 2003; 4:1535-1541.